PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO) today announced that five abstracts will be presented or published at upcoming major medical meetings. The data will include various Phase 1 clinical results for QUADRAMET® (samarium Sm-153 lexidronam injection) in combination settings for the treatment of metastatic bone disease arising from prostate cancer and multiple myeloma, as well as data from a study evaluating the outcomes of prostate cancer patients based on the findings of PROSTASCINT® (capromab pendetide) imaging. These presentations underscore Cytogen’s strategy to maximize the market potential of its approved products through data-driven initiatives.
